Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.705 SEK | +0.37% | -2.70% | -64.69% |
Sales 2024 * | 82.38M 7.73M | Sales 2025 * | 196M 18.38M | Capitalization | 591M 55.49M |
---|---|---|---|---|---|
Net income 2024 * | -244M -22.91M | Net income 2025 * | -174M -16.33M | EV / Sales 2024 * | 5.5 x |
Net cash position 2024 * | 138M 12.99M | Net Debt 2025 * | 62.58M 5.87M | EV / Sales 2025 * | 3.34 x |
P/E ratio 2024 * |
-1.77
x | P/E ratio 2025 * |
-2.58
x | Employees | 57 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.3% |
Latest transcript on Oncopeptides AB
1 day | +0.37% | ||
1 week | -2.70% | ||
Current month | -7.04% | ||
1 month | -15.99% | ||
3 months | -48.50% | ||
6 months | -68.62% | ||
Current year | -64.69% |
Managers | Title | Age | Since |
---|---|---|---|
Sofia Heigis
CEO | Chief Executive Officer | 44 | 20-07-31 |
Director of Finance/CFO | 50 | Nov. 12 | |
Eva Nordström
COO | Chief Operating Officer | 54 | 11-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Per Wold-Olsen
CHM | Chairman | 76 | 18-05-16 |
Director/Board Member | 63 | 11-12-31 | |
Director/Board Member | 61 | 17-01-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 2.705 | +0.37% | 807 406 |
24-05-23 | 2.695 | -0.92% | 1,012,590 |
24-05-22 | 2.72 | -2.51% | 1,885,695 |
24-05-21 | 2.79 | +1.45% | 1,197,190 |
24-05-20 | 2.75 | -1.08% | 1,513,588 |
Delayed Quote Nasdaq Stockholm, May 24, 2024 at 11:29 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-64.69% | 55.05M | |
+12.19% | 116B | |
+12.64% | 106B | |
-9.39% | 23.89B | |
-1.69% | 21.58B | |
-10.60% | 18.96B | |
-41.25% | 16.96B | |
-15.28% | 16.33B | |
+6.27% | 14.14B | |
+29.81% | 12.02B |
- Stock Market
- Equities
- ONCO Stock